Dr. Fordyce brings more than 15 years’ experience leading teams in drug discovery, development, clinical translation, and commercialization of new treatments.
Before founding Vera, Fordyce was the founder and CEO of gene-editing company Trucode Gene Repair, Inc., having previously served as an entrepreneur in residence at Kleiner Perkins Caufield and Byers.
Earlier in his career, Fordyce served as Senior Director of clinical research at Gilead Sciences, Inc., where he contributed to seven new drug approvals and served as project lead for Gilead’s TAF/GENVOYA development program.
With subspecialty training in infectious disease from Columbia University Vagelos College of Physicians and Surgeons, Fordyce was previously Chief Resident at NYU Bellevue and spent two years as a translational research fellow at Rockefeller University.
Fordyce currently serves on the Board of Directors of the Albert and Mary Lasker Foundation. He received his BA from Harvard University and his MD from Harvard Medical School.
What is Marshall Fordyce's net worth?
The estimated net worth of Marshall Fordyce is at least $15.26 million as of October 23rd, 2024. Dr. Fordyce owns 307,972 shares of Vera Therapeutics stock worth more than $15,260,013 as of December 3rd. This net worth approximation does not reflect any other investments that Dr. Fordyce may own. Additionally, Dr. Fordyce receives a salary of $910,140.00 as CEO and Founder at Vera Therapeutics. Learn More about Marshall Fordyce's net worth.
How old is Marshall Fordyce?
What is Marshall Fordyce's salary?
How do I contact Marshall Fordyce?
Has Marshall Fordyce been buying or selling shares of Vera Therapeutics?
Within the last three months, Marshall Fordyce has sold $1,380,056.25 of Vera Therapeutics stock. Most recently, Marshall Fordyce sold 19,375 shares of the business's stock in a transaction on Wednesday, October 23rd. The shares were sold at an average price of $40.39, for a transaction totalling $782,556.25. Following the completion of the sale, the chief executive officer now directly owns 307,972 shares of the company's stock, valued at $12,438,989.08. Learn More on Marshall Fordyce's trading history.
Who are Vera Therapeutics' active insiders?
Are insiders buying or selling shares of Vera Therapeutics?
In the last year, Vera Therapeutics insiders bought shares 1 times. They purchased a total of 161,290 shares worth more than $4,999,990.00. In the last year, insiders at the sold shares 12 times. They sold a total of 1,680,949 shares worth more than $44,809,507.61. The most recent insider tranaction occured on October, 28th when Director Beth C Seidenberg sold 15,000 shares worth more than $720,450.00. Insiders at Vera Therapeutics own 21.7% of the company.
Learn More about insider trades at Vera Therapeutics. Information on this page was last updated on 10/28/2024.
